Boston Scientific Stock Fair Value Calculation – Boston Scientific Reports Q2 Earnings for FY2023
August 20, 2023
🌥️Earnings Overview
On June 30th 2023, BOSTON SCIENTIFIC ($NYSE:BSX) announced their earnings results for the second quarter of FY2023, with total revenue reaching USD 3599.0 million, a 10.9% increase compared to the prior year’s same period. In addition, net income was USD 270.0 million, a 3.8% rise from the same period in the prior year.
Stock Price
On Thursday, Boston Scientific reported its second quarter earnings for the fiscal year of 2023. The healthcare technology company’s stock opened at $53.2 and closed at $52.6, a 0.5% increase from the prior closing price of $52.4. While the slight uptick in Boston Scientific’s stock price may have been modest, it was a positive sign to investors that the company’s second quarter earnings are in line with expectations. The earnings report provided further evidence that Boston Scientific is continuing to grow its business and remain a leader in the healthcare technology space. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Boston Scientific. More…
| Total Revenues | Net Income | Net Margin |
| 13.4k | 861 | 8.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Boston Scientific. More…
| Operations | Investing | Financing |
| 1.77k | -2.01k | -548 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Boston Scientific. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 32.89k | 14.78k | 12.42 |
Key Ratios Snapshot
Some of the financial key ratios for Boston Scientific are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 9.7% | 27.7% | 13.2% |
| FCF Margin | ROE | ROA |
| 8.7% | 6.2% | 3.4% |
Analysis – Boston Scientific Stock Fair Value Calculation
At GoodWhale, we believe in ensuring the wellbeing of our clients and partners. Therefore, we conducted an analysis of BOSTON SCIENTIFIC‘s wellbeing to determine its fair value. After our thorough review, we concluded that the fair value of a single share of BOSTON SCIENTIFIC is around $47.4, calculated by our proprietary Valuation Line. Currently, BOSTON SCIENTIFIC stock is being traded at $52.6, a fair price that is overvalued by 11.0%. We hope that this analysis can help guide BOSTON SCIENTIFIC investors in making informed decisions. More…
Peers
Boston Scientific Corp is one of the leading competitors in the medical device industry. Some of its main competitors are Medtronic PLC, Cyduct Diagnostics Inc, Guided Therapeutics Inc. Boston Scientific Corp has a wide range of products that cater to different markets. This gives the company a competitive advantage over its competitors.
– Medtronic PLC ($NYSE:MDT)
As of 2022, Medtronic PLC has a market cap of 111.05B and a Return on Equity of 7.49%. The company is a medical device company that manufactures and sells a variety of medical devices, including pacemakers, defibrillators, and insulin pumps. Medtronic PLC is headquartered in Dublin, Ireland.
– Cyduct Diagnostics Inc ($OTCPK:CYDX)
Cyduct Diagnostics Inc is a publicly traded company that provides diagnostic testing services. The company’s market cap as of 2022 was 349.68k. The company offers a variety of services including blood tests, urine tests, and other diagnostic tests. Cyduct Diagnostics Inc is headquartered in the United States.
– Guided Therapeutics Inc ($OTCPK:GTHP)
Guided Therapeutics, Inc., a molecular diagnostics company, focuses on the development and commercialization of molecularly targeted photodynamic therapies for the treatment of pre-cancerous lesions and cancer. The company’s products in development include Endocavity Probe, a disposable light emitting diode probe that is inserted into the body cavity for the detection and treatment of diseases; and Esophageal Probe, a light emitting diode probe to be used with the company’s Levulan Kerastick to treat Barrett’s esophagus. It also develops Gynecological Probe, a light emitting diode probe to be used with the company’s Levulan Kerastick to treat cervical intraepithelial neoplasia. The company was formerly known as Light Touch Medical, Inc. and changed its name to Guided Therapeutics, Inc. in November 2009. Guided Therapeutics, Inc. was founded in 1998 and is based in Atlanta, Georgia.
Summary
Boston Scientific has demonstrated strong financial growth in the second quarter of FY2023, with total revenue increasing by 10.9% year-over-year and net income rising by 3.8%. This is encouraging news for potential investors looking for a well-performing and reliable long-term investment. Boston Scientific has consistently delivered solid results and demonstrated sound management of its assets, making it an attractive option for investors seeking to diversify their portfolio. With the company continuing to show positive momentum, Boston Scientific is a smart choice for those seeking a secure and profitable investment.
